Malaysia Biotech CCM Duopharma Announces Expansion Plans
This article was originally published in PharmAsia News
Executive Summary
Malaysia's CCM Duopharma Biotech says it plans to spend $23.1 million over the next three years to expand its plant to accommodate its growth expectations. In addition to expanding its production capacity, CCMD also plans to buy new machinery, upgrade amenities and improve its warehousing and waste-water treatment facilities. The result, it says, should be increased capacity for producing injectables, liquids and ampule-packing capacity. (Click here for more
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.